Are These On Your List Of Penny Stocks Right Now?
Do you know where to buy penny stocks? If you’re new to stocks under $5, then it’s a valid question. To be honest, the options available in the stock market today are plentiful. Just look for some of the top penny stock brokers. Interactive Brokers, TD Ameritrade, ETrade, Robinhood, WeBull, and others allow you to buy penny stocks. While fees will vary, many already allow a freemium model to trade in the stock market.
If you’re wondering where to buy penny stocks in reference to where to find them, let’s explain. Stocks, whether under or over $5, trade on exchanges. These exchanges are accessible via a broker. The ones mentioned above will give you access to search for penny stocks, for example, right on their platform.
- Beginner’s Guide To Trading Penny Stocks in 2020
- Penny Stock Wah Fu Education Group Up 598% Overnight; Now What?
- Are These The Best Penny Stocks To Buy Under $2.50?
There’s usually a search box where you can enter in the 1, 2, 3, 4, or 5 letter stock symbol. It should then give you a result showing at least share price and volume
Can You Make Money With Penny Stocks?
I know this may seem basic to some but there’s been a huge awareness push on small-cap stocks lately. So before we get into the list of penny stocks, I wanted to address some basics. In any case, once you find the penny stocks you like, you’ll want to monitor them before jumping right in.
So make sure you understand some important things to take note of. This includes things like volume, price, and what the potential catalyst was for the move. But professional traders also focus on chart patterns and capturing profit throughout the entire trade; not just “when it starts going down”:
We’re not going to get into trading basics in this article. But if you are interested in learning more about penny stocks, we’ve got 60+ pages discussing penny stocks in a free ebook for subscribers. Now, let’s take a look at some penny stocks right now turning heads. Will they be the best ones to buy before next week? I’ll leave that up to you.
Penny Stocks To Watch: IZEA Worldwide, Inc.
IZEA Worldwide, Inc. (IZEA Stock Report) has been one of the top penny stocks to watch since early May on our site. If you want to get caught up on everything, click here for more articles on IZEA stock. In any event, since May 4th, the penny stock has been on the move. Where shares of IZEA stock were trading around $0.31 and that has dramatically changed in just a little over a month. In fact, premarket highs on Thursday, the penny stock reached a high of $3. What’s been driving momentum?
Accounting for speculative hype, IZEA is focused on expanding its footprint and targeting growth. Toward the end of May, IZEA announced that it established a new relationship with a “Fortune 500 insurance company” for influencer marketing services. IZEA said it also expanded its relationships with a “Fortune 100 food manufacturer” and a leading “multi-billion-dollar furniture goods manufacturer,” among others.
Why could IZEA be one of the penny stocks to watch right now? Earlier this week, the company announced it received renewed commitments from two global retailers. One retailer is a Fortune 500 company, the other a Fortune 10 company. On top of that, this Friday, IZEA “plans to make” a special announcement that will also see a follow-up conference call on June 18th to further discuss. That has traders focused on what’s coming next.
Penny Stocks To Watch: Onconova Therapeutics
Another one of the penny stocks to watch this quarter is Onconova Therapeutics Inc. (ONTX Stock Report). ONTX stock was trending back in late-March and was originally why it caught some attention. At the time, the penny stock traded around $0.33 and the company was gaining attention ahead of its last earnings report. Fast-forward to this week and a lot has materialized. Investors were bullish after ONTX reported earnings and that continued to boost optimism with analysts.
As a clinical-stage biotechnology penny stock, there’s not much by way of revenue. This is normal for early-stage companies. So it’s important to pay attention to guidance and milestones from the quarter. Aside from that, also pay attention to near-term potential catalysts. Specifically, Steven M. Fruchtmand, M.D., President and Chief Executive Officer explained that with enrollment completed in March, “Onconova’s pivotal Phase 3 INSPIRE trial is advancing to the next catalyst.”
Following the earnings, Maxim analysts upgraded ONTX stock to Buy from hold in May. This week, Avi Oler, Senior Vice President, Corporate Development, presents at BIO Digital 2020. He’ll be giving an overview of the company’s objectives and upcoming milestones. Furthermore, a look at its filings shows more. An 8-K (material event) filed on June 10 shows the company “intends to defer any reverse stock split until topline data from its pivotal Phase 3 “INSPIRE” trial are announced or as required by the Nasdaq Stock Market.”
The Phase 3 trial is expected during the second half of 2020 and Onconova has until August 17, 2020 to regain NASDAQ compliance. In light of this, ONTX stock has tested its 20Day Moving average for the first time since last June. Will this signal a new bull trend for the stock or is it set to slide back again?
Penny Stocks To Watch: Celldex Therapeutics
While Celldex Therapeutics (CLDX Stock Report) left the price range of “penny stocks” this afternoon, it has been one of the high-volume penny stocks to watch this month. If you remember when we talked about it at the end of May, it was on a “List of Penny Stocks To Watch In June.” Why? First, results from the Phase 1 study of CDX-0159 were accepted as a late-breaking poster presentation at the European Academy of Allergy and Clinical Immunology. That was held from June 6-8, 2020.
Celldex also said it’s also completing preparations to advance its CDX-527. The treatment is the first candidate from its bispecific platform. The company aims to push it into a Phase 1 study in refractory, advanced cancers slated for the second half of the year. Since we’re at the halfway point of the year, “H2” events are in focus. This week, CLDX stock continued its bullishness after another breakthrough development.
Celldex filings revealed that insiders are buying up shares of CLDX stock. Certain Directors and Officers including CEO Anthony Marucci bought up over $100,000 worth of shares as reported by FORM4s June 10 and 11th. Obviously, insider buying gives the public insight into how management views its own company.
Considering that the average purchase price was around $3, the current PPS is significantly higher. Since our May update, we’ve seen CLDX stock rally from $2.63 to highs of over $7. Will the trend continue or will there be a big pullback to come? Let us know what you think in the comments below.